Back to Browse Journals » Research and Reports in Biodiversity Studies » Volume 1

Biodiversity: crises past and present, and future challenges

Authors Lane DJW

Published Date June 2011 Volume 2011:1 Pages 1—2

DOI http://dx.doi.org/10.2147/RRBS.S19443

Published 22 June 2011

David JW Lane
Department of Biology, Universiti Brunei Darussalam, Brunei Darussalam

This inaugural issue of a new biodiversity journal, Research and Reports in Biodiversity Studies (RRBS), is one of many new scientific Journals that are appearing and competing for ratings in the academic arena. Librarians, institutes of higher education, and funding agencies might despair of being able to source the funding needed to sustain institutional subscriptions or authorship fees for new journals, yet, as indicated below, there has never, unfortunately, been a greater need for advancing and reporting knowledge of biodiversity, its preservation, and its presentation to a wide audience. Open-access journals, such as this one, provide an ideal platform for alerting the scientific and media world to biodiversity issues and the growing threats to the world's living heritage. RRBS, with its open-access, electronic format, has several advantages over traditional subscription-based journals for disseminating new ideas, discoveries, and status reports on biodiversity. For example, while maintaining quality of peer review, throughput times are rapid, articles are not rejected due lack of space, and (being online) expensive production costs for graphics are virtually eliminated. And, of course, articles have free, unrestricted access. This niche in the publishing world and RMBR, specifically, consequently provides a much-needed venue for perhaps one of the most important topics for all humanity today - that of biodiversity.

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets

Kim JY, Lee SH, Park CW, Rhee YS, Kim DW, Park J, Lee M, Seo JW, Park ES

Drug Design, Development and Therapy 2015, 9:695-706

Published Date: 30 January 2015

Progressive osseous heteroplasia: diagnosis, treatment, and prognosis

Pignolo RJ, Ramaswamy G, Fong JT, Shore EM, Kaplan FS

The Application of Clinical Genetics 2015, 8:37-48

Published Date: 30 January 2015

Diabetes reversal via gene transfer: building on successes in animal models

Gerace D, Martiniello-Wilks R, Simpson AM

Research and Reports in Endocrine Disorders 2015, 5:15-29

Published Date: 29 January 2015

Photothermal cancer therapy using graphitic carbon–coated magnetic particles prepared by one-pot synthesis

Lee HJ, Sanetuntikul J, Choi ES, Lee BR, Kim JH, Kim E, Shanmugam S

International Journal of Nanomedicine 2015, 10:271-282

Published Date: 30 December 2014

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011

Difluprednate ophthalmic emulsion 0.05% (Durezol®) administered two times daily for managing ocular inflammation and pain following cataract surgery

Stephen Smith, Douglas Lorenz, James Peace, et al.

Clinical Ophthalmology 2010, 4:983-991

Published Date: 30 August 2010